Benzinga | Aug 10, 2021 06:05AM EDT

Morgan Stanley Initiates Coverage On TScan Therapeutics with Overweight Rating, Announces Price Target of $22

Morgan Stanley analyst Vikram Purohit initiates coverage on TScan Therapeutics (NASDAQ:TCRX) with a Overweight rating and announces Price Target of $22.